Development of an inactivated vaccine candidate for SARS-CoV-2

Qiang Gao(Sinovac Biotech), Linlin Bao(Chinese Academy of Medical Sciences & Peking Union Medical College), Haiyan Mao(Zhejiang Center for Disease Control and Prevention), Lin Wang(Sinovac Biotech), Kangwei Xu(National Institutes for Food and Drug Control), Minnan Yang(Chinese Academy of Sciences), Yajing Li(Sinovac Biotech), Ling Zhu(Chinese Academy of Sciences), Nan Wang(Chinese Academy of Sciences), Zhe Lv(Chinese Academy of Sciences), Hong Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoqin Ge(Sinovac Biotech), Biao Kan(National Institute for Communicable Disease Control and Prevention), Yaling Hu(Sinovac Biotech), Jiangning Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Fang Cai(Sinovac Biotech), Deyu Jiang(Sinovac Biotech), Yanhui Yin(Sinovac Biotech), Cheng‐Feng Qin(Chinese Academy of Medical Sciences & Peking Union Medical College), Chengfeng Qin(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Li(Sinovac Biotech), Xuejie Gong(Sinovac Biotech), Xiuyu Lou(Zhejiang Center for Disease Control and Prevention), Wen Shi(Sinovac Biotech), Dongdong Wu(Sinovac Biotech), Hengming Zhang(Sinovac Biotech), Lang Zhu(Chinese Academy of Sciences), Wei Deng(Chinese Academy of Medical Sciences & Peking Union Medical College), Yurong Li(Sinovac Biotech), Jinxing Lu(National Institutes for Food and Drug Control), Changgui Li(Chinese Academy of Sciences), Xiangxi Wang(Chinese Academy of Sciences), Weidong Yin(Sinovac Biotech), Yanjun Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Chuan Qin(Chinese Academy of Medical Sciences & Peking Union Medical College), Chuan Qin(Chinese Academy of Medical Sciences & Peking Union Medical College)
Science
May 6, 2020
10.1126/science.abc1932
Cited by 1,517Open Access
Full Text

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.

Related Papers

No related papers found

Powered by citation graph analysis